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Abstract
Aggressive chemotherapy has improved the life expectancy for
reproductive-age women with breast cancer, but it often causes
infertility or premature ovarian failure due to destruction of the
ovarian reserve. Many questions concerning fertility preservation in
breast cancer patients remain unanswered – for example, whether
fertility preservation methods interfere with chemotherapy, and
whether subsequent pregnancy has negative effects on the
prognosis. Fertility preservation is a critical factor in decision-
making for younger breast cancer patients, however, and clinicians
should address this. The present article reviews the incidence of
chemotherapy-induced amenorrhea, and discusses fertility-
preservation options and the prognosis for patients who become
pregnant after breast cancer.
Introduction
Breast cancer is the most common malignancy in women of
reproductive age, and about 13% of all breast cancer
diagnoses are made in women younger than age 45 years
[1]. In Germany, the average age of primiparas is 29.8 years
[2], which means that many breast cancer patients have not
completed their family planning and wish to have children
after the diagnosis of breast cancer. The majority of women
diagnosed with early-stage breast cancer today have an
excellent long-term prognosis, but many of them will undergo
a temporary or permanent cessation of menses. Although
premature ovarian insufficiency can improve the breast
cancer prognosis for women with hormone-positive breast
cancer, these women have to face subsequent infertility and
many psychological problems [3].
In the present review, we discuss the effect of the most up-to-
date chemotherapy regimens for breast cancer on fertility,
and we analyze the options for fertility preservation, as well as
the various in vitro fertilization (IVF) protocols that can be
applied in this specific patient group. Finally, a review of the
available studies on the effect of a subsequent pregnancy on
the outcome in breast cancer survivors is conducted.
Effect of chemotherapy for breast cancer on
fertility
This section discusses the effect on fertility of chemotherapy
for breast cancer (Table 1) [4–13]. The risk of chemotherapy-
related amenorrhea depends on the patient’s age, on the
specific chemotherapeutic agents used, and on the total
dose administered. Older women have a higher incidence of
complete ovarian failure and permanent infertility in
comparison with younger women [14]. This higher incidence
can be explained by younger women’s larger primordial
follicle reserve, which declines with age.
With regard to the chemotherapy regimen, according to
Meirow, alkylating agents (for example, cyclophosphamide)
involve the greatest risk for inducing ovarian failure among all
chemotherapeutic agents (odds ratio 3.98 in comparison
with unexposed patients) [15]. The higher the cumulative
dose of cyclophosphamide, the higher the observed inci-
dence of menopause. Goldhirsch and colleagues reported
that, with the classic cyclophosphamide, methotrexate, and
5-fluorouracil (CMF) regimen, the incidence of amenorrhea
was 61% in patients aged <40 years and was 95% in
patients aged >40 years [4].
The classic fluorouracil, epirubicin, and cyclophosphamide
regimen (intravenous administration on day 1 of all drugs for
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six cycles, cyclophosphamide 600 mg/m2, epirubicin 60 mg/m2,
fluorouracil 600 mg/m2) induces menopause in 60% of
patients [11].
The National Cancer Institute of Canada adjuvant trial com-
paring CMF with the fluorouracil, epirubicin, and cyclophos-
phamide regimen indicated that the incidence of amenorrhea
was slightly higher in the fluorouracil, epirubicin, and cyclo-
phosphamide arm (51%) in comparison with the CMF arm
(42.6%) [6]. This arm was a dose-intensified fluorouracil,
epirubicin, and cyclophosphamide regimen (cyclophospha-
mide 75 mg/m2 orally on days 1 to 14, epirubicin 60 mg/m2
intravenously on days 1 and 8, and fluorouracil 500 mg/m2
intravenously on days 1 and 8), given for six cycles.
Most anthracycline-based regimens are associated with a
lower incidence of amenorrhea, most probably due to the
lower cumulative cyclophosphamide dosages used in com-
parison with the classic CMF regimen. The doxorubicin and
cyclophosphamide regimen (adriamycin (doxorubicin), and
cyclophosphamide) has been reported by Bines and
colleagues to result in amenorrhea at a rate of 34% [5].
With regard to the taxanes, a study including 191 patients
showed that older age and the addition of taxane to adria-
mycin and cyclophosphamide increased the risk of
chemotherapy-induced amenorrhea, and that the amenorrhea
was more likely to be irreversible for women over 40 years old
[13]. Younger women often resume menstruation even after
Table 1
Incidence of amenorrhea induced by the most commonly used chemotherapy regimens in breast cancer
Follow-up to  Rate of amenorrhea
Duration of  definite 
Patients Chemotherapy  treatment  amenorrhea  Age 
Reference Year (n) regimen (months) (months) Percentage (years)
Goldhirsch and colleagues [4] 1990 541 CMF 1 9 14/34 <40/>40
387 6 33/81 <40/>40
Bines and colleagues [5] 1996 3,628 CMF 3 to 24 12 40/76 <40/>40
Levine and colleagues [6] 1998 359 CMF 6 NA 42.6
132 FEC 6
Goodwin and colleagues [7] 1999 83 CMF 6 12 55.6
25 FEC 6 64.6
Nabholtz and colleagues [8] 2002 745 ACD 6 33 51.4
746 FAC 6
Fornier and colleagues [9] 2005 84 AC-T/D 6 12 13
82 AC-T/D + tamoxifen 17
Martin and colleagues [10] 2005 420 ACD 6 NA 61.7
403 FAC 52.4
Venturini and colleagues [11] 2005 503 FEC 4 120 64
Petrek and colleagues [12] 2006 120 AC 4 36 53
168 ACT 6 42
83 CMF 8 82
38 FAC 6 NA
34 FACT 6 NA
19 ACD 6 45
Tham and colleagues [13] 2007 75 AC 4 12 44/81 <40/>40
116 AC + T/D 4 + 3 61/85 <40/>40
Total 8,681
AC, adriamycin (doxorubicin), and cyclophosphamide; ACD, adriamycin (doxurubicin), cyclophosphamide and docetaxel; AC-T/D, adriamycin
(doxorubicin), cyclophosphamide and taxol (paclitaxel)/docetaxel; CMF, cyclophosphamide, methotrexate, and 5-fluorouracil; FAC, 5-fluorouracil,
adriamycin (doxorubicin), and cyclophosphamide; FACT, 5-fluorouracil, adriamycin (doxorubicin), cyclophosphamide and taxol (paclitaxel); FEC, 5-
fluorouracil, epirubicin, and cyclophosphamide; NA, not available.Page 3 of 11
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6 months of amenorrhea, and the addition of a taxane does
not play a role [13]. Some other studies have evaluated the
impact of the addition of paclitaxel or docetaxel
[9,10,12,16–18]. These limited data suggest that, when age
is controlled for, adding a taxane to adriamycin and
cyclophosphamide-type chemotherapy has little if any effect
on the subsequent risk of chemotherapy-related amenorrhea.
Taxanes inhibit the function of the mitotic spindle and appear
to have an even lower likelihood of resulting in persistent
ovarian dysfunction [19].
With regard to trastuzumab, a preliminary study evaluating
the risks of the most up-to-date treatment modalities found
that the addition of trastuzumab did not have a detrimental
affect on fertility [18].
Another recent prospective cohort survey study evaluated
595 women aged 25 to 40 years who were treated for early
breast cancer with different chemotherapy regimens [12].
The study found that menstrual cycles were more likely to
persist among women treated with regimens that contained
less total cyclophosphamide, such as adriamycin and cyclo-
phosphamide, or taxol (paclitaxel), adriamycin, and cyclo-
phosphamide, or docetaxel, adriamycin, and cyclophos-
phamide. While women who were on CMF treatment were
more likely than those on adriamycin and cyclophosphamide,
those on docetaxel, adriamycin, and cyclophosphamide, or
those on taxol, adriamycin, and cyclophosphamide to bleed
during the first month following chemotherapy (approximately
50% versus 20%; odds ratio, 2.9; 95% confidence interval
(CI), 1.7 to 5), the likelihood of menses 1 year later was lower
in the CMF group (odds ratio, 0.37; 95% CI, 0.37 to 0.67).
The study also revealed that tamoxifen accounted for a
modest but significant decrease (15%) in menstrual cycling
at 1 year and 2 years, regardless of the chemotherapy
program. Premenopausal women generally continue to
menstruate while receiving tamoxifen, although menses can
become irregular. The effect on the ovary is assumed to be
reversible and temporary [12].
Fertility preservation strategies
The most effective approach to date is embryo cryo-
preservation. The human embryo is very resistant to damage
caused by cryopreservation. The post-thaw survival rate of
embryos is in the range of 35% to 90%, while implantation
rates are between 8% and 30%; if multiple embryos are
available for cryopreservation, cumulative pregnancy rates
can be more than 60% [20]. Delivery rates per embryo
transfer using cryopreserved embryos are reported to be in
the range of 18% to 20% [20]. This approach, however,
requires IVF and a participating male partner. If many mature
oocytes are retrieved, there is an opportunity to carry out
several attempts at embryo transfer from a single cycle. This
option may not be acceptable for prepubertal adolescent
girls [21].
Cryopreservation of mature oocytes after gonadotropin
stimulation
Oocyte banking is more problematic than cryopreservation of
sperms or embryos. The first obstacle is the sensitivity of
oocytes to chilling, probably because of the sensitivity of the
spindle apparatus and the higher lipid content of the cells.
Cooling and exposure to cryoprotecting agents affect the
cytoskeleton and may aggravate the already high incidence of
aneuploidy in human oocytes [22]. Exposure to cryoprotec-
ting agents also causes hardening of the zona pellucida, so
that all oocyte cryopreservation protocols involve intracyto-
plasmic sperm injection as a precaution. Fertilization has to
be carried out about 3 to 5 hours after thawing while the
oocyte remains fertile.
Further disadvantages of this method are that cancer patients
may not have more than one opportunity for oocyte
harvesting before undergoing potentially sterilizing treatment,
since a cycle of controlled stimulation requires several weeks,
and there is normally a delay of a few months before
treatment cycles. The success of the method is also
dependent on the total number of eggs harvested (<10
oocytes means very low chances of pregnancy).
With the introduction of intracytoplasmic sperm injection and
the publication of reassuring data [23], however, efforts to
cryopreserve oocytes have resumed in recent years – with
conventional slow cooling–rapid thawing protocols, and later
with vitrification. More than 4,300 oocytes have been cryo-
preserved and more than 80 children have been born to date,
mostly with the conventional slow cooling method. The overall
live birth rate per cryopreserved oocyte is about 2%, which is
much lower than that with IVF using fresh oocytes [24].
These data were confirmed by a recent meta-analysis by
Oktay and colleagues, who found that the live birth rate per
injected oocyte was approximately 2% with the most
commonly used slow-freezing technique. Pregnancy rates
were one-third to one-quarter of the success rates seen with
unfrozen oocytes [25].
A further alternative, which is still at an experimental stage, is
the cryopreservation of immature oocytes (with or without in
vitro maturation). This method is currently still associated with
a relatively low pregnancy rate, as well as a high rate of
miscarriages [26].
Several small studies have evaluated the utility of gonado-
tropin-releasing hormone receptor (GnRH) analogue treat-
ment to preserve ovarian function during cytotoxic therapy,
including among women with breast cancer (Table 2)
[27–30]. This research has suggested that receiving GnRH
analogue throughout treatment may increase a woman’s
likelihood of remaining premenopausal after chemotherapy,
although there has been intensive debate concerning the
existence of follicle-stimulating hormone (FSH) receptors in
Available online http://breast-cancer-research.com/content/10/2/206primordial follicles and GnRH analogue receptors in the
human ovary [31,32].
GnRH analogue treatment appeared to reduce the incidence
of amenorrhea in a population of relatively older reproductive-
age women, but the reproductive outcome was poor. Twenty-
three of the 24 women resumed menstruation after receiving
a GnRH analogue along with chemotherapy, and went on to
attempt to conceive. Six pregnancies occurred in five
patients; three pregnancies resulted in miscarriage, one
pregnancy was terminated because of Down’s syndrome,
one pregnancy was ongoing, and one woman delivered [27].
A retrospective evaluation by Recchia and colleagues
included 100 consecutive premenopausal women (median
age 43 years) with high-risk early breast carcinoma who
received a GnRH analogue for ovarian protection during
adjuvant chemotherapy [29]. After a median follow-up of
75 months, normal menses were resumed by all patients
under the age of 40 years and by 56% of patients older than
40 years. Three pregnancies were observed, which resulted
in two normal deliveries and one voluntary abortion. The
projected recurrence-free survival rates at 5 years and at
10 years were 84% and 76%, respectively, and the projected
overall survival rates at 5 and 10 years were 96% and 91%,
respectively [29].
In a single-center, prospective, single-arm, phase II study in
29 premenopausal women (median age 38 years) with early
breast carcinoma who received GnRH analogue for ovarian
protection during adjuvant chemotherapy, after a median
follow-up of 72 months, normal menses were resumed in
94% (16/17) of patients under the age of 40 years and by
42% (5/12) of patients older than 40 years [28].
In a very recent prospective, single-arm study by Urruti-
coechea and colleagues including 50 women who received
combination anthracycline-containing chemotherapy regimens
with a mean cumulative cyclophosphamide dose of 3.9 g/m2
and concurrent goserelin administration, amenorrhea
occurred in all but one patient. Forty-five patients (90%)
recovered menstruation during the first year of follow-up, with
a mean time to recovery of 5 months. Ten of the women
attempted to become pregnant, resulting in eight preg-
nancies in seven patients [30].
The available studies are limited, however, by their small
sample sizes, by the lack of a randomized control group, and
by the lack of definitive information regarding actual fertility
outcomes. Randomized controlled trials are currently
underway internationally to evaluate this strategy in women
with cancer.
The Southwestern Oncology Group is running an ongoing
randomized evaluation among women with hormone receptor-
negative Stage I–IIIA breast cancer who are either receiving
or not receiving goserelin during treatment. In the United
Kingdom, the Ovarian Protection for Premenopausal Women
having Chemotherapy for Breast Cancer (OPTION) trial is
similar, but is also including women with hormone receptor-
positive disease. The potential benefit of ovarian suppression
in addition to tamoxifen for women with hormone receptor-
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Table 2
Published studies of ovarian suppression with gonadotropin-releasing hormone agonists
Menses Menses 
1 year  at the 
after end  of 
Patients Chemotherapy  Pregnancies  Births  therapy follow-up
Reference Year (n) regimen (%) (%) (%) (%) Study type Outcome
Fox and  2003 24 AC, AC-T, FAC,  21 8 96 75 Prospective,  Ovarian function 
colleagues [27] AT-CMF single-arm preservation
Del Mastro and  2006 29 100% FEC – – 94 92 Prospective,  Ovarian function 
colleagues [28] single-arm preservation
Recchia and  2002 100 26% CMF,  3 2 100 Retrospective,  Ovarian function
colleagues [29] 11% FEC,  single-arm  preservation
54% CMF + epirubicin, 
9% HCST
Urruticoechea  2007 50 78% FEC, 14% AC,  16 16 86 90 Prospective,  Ovarian function 
and colleagues [30] 8% AC-T/D single-arm  preservation
Total 203
AC, adriamycin (doxorubicin), and cyclophosphamide; AC-T, adriamycin (doxorubicin), cyclophosphamide and taxol (paclitaxel); AC-T/D,
adriamycin (doxorubicin), cyclophosphamide and taxol (paclitaxel)/docetaxel; AT-CMF, adriamycin (doxorubicin), taxol (paclitaxel),
cyclophosphamide, methotrexate, and 5-fluorouracil; CMF, cyclophosphamide, methotrexate, and 5-fluorouracil; FAC, 5-fluorouracil, adriamycin
(doxorubicin), and cyclophosphamide; FEC, 5-fluorouracil, epirubicin, and cyclophosphamide; HCST, high dose chemotherapy and autologous
peripheral blood progenitor cell transplantation.positive breast cancer is currently under active investigation
in the Suppression of Ovarian Function Trial. Other pros-
pective randomized trials – such as the Zoladex Rescue of
Ovarian Function study in Germany, the Italian multicenter
study for breast cancer patients, the German Hodgkin
Lymphoma Group multicenter study, the UK lymphoma
multicenter study, the Spanish lymphoma multicenter study,
and the Prevention of Gonadal Toxicity and Preservation of
Gonadal Function and Fertility in Young Women with
Systemic Lupus Erythematosus Treated by Cyclophos-
phamide (PREGO) study – can be expected to provide
definitive evidence of the role of GnRH analogue in ovarian
function preservation [32].
In a recent, very interesting, review by Oktay and colleagues
[32], the possible hazards of GnRH analogue treatment for
fertility preservation purposes have been sufficiently
described. GnRH analogues are not only expensive and
cause severe menopausal symptoms, but in addition the
direct effects of GnRH agonists on human cancer cells are
not adequately understood. A variety of human cancers,
including those of the breast, the ovary, and the endometrium,
express GnRH receptors. These receptors mediate several
effects, such as inhibition of proliferation, induction of cell-
cycle arrest, and inhibition of apoptosis induced, for example,
by cytotoxic drugs [33]. The possibility therefore cannot be
excluded that GnRH agonist therapy concomitant with
cytotoxic chemotherapy might reduce the efficacy of chemo-
therapy for breast cancer. There are data from randomized
studies, however, as well as the results of the Early Breast
Cancer Trialists’ Collaborative Group meta-analysis and the
results of the LHRH-agonists in Early Breast Cancer
Overview group, that have not shown a different outcome in
patients who received ovarian suppression concurrent with
the chemotherapy in comparison with patients treated with
chemotherapy alone [34-36].
At a more practical level, up to 97% of patients suffer from
hypoestrogenic symptoms when using a GnRH analogue
along with chemotherapy [28]. Furthermore, when the
analogue is used for >4 months, patients may experience
bone loss, which may not be reversible with longer periods of
use [37].
The American Society of Clinical Oncology has pointed out
that there is at present insufficient evidence regarding the
safety and effectiveness of GnRH analogues and other
methods of ovarian suppression on female fertility preser-
vation. The Society recommends that women who are
interested in ovarian suppression for this purpose should be
encouraged to participate in clinical trials [38].
At present, cryopreservation of ovarian tissue appears a very
promising method of providing the cancer patient with a
realistic chance of fertility preservation – a prospect that is
also extremely important for psychological reasons [39].
The cryopreservation of ovarian cortical strips has recently
emerged as an easy, fast, and inexpensive technique, and has
already yielded the first two livebirths [40,41]. The idea of
cryopreserving ovarian tissue is based on the finding that the
ovarian cortex harbors primordial follicles that are more
resistant to cryoinjury than mature oocytes, because the
oocytes they contain have a relatively inactive metabolism and
lack a metaphase spindle, zona pellucida, and cortical
granules [42]. The clinical indications are almost identical
with those for the oocyte, but there are fewer logistical
restrictions and there is a greater fertility potential, because of
the far larger number of oocytes preserved. Ovarian tissue
cryopreservation may be the only acceptable method for any
prepubertal or premenarchal female patients receiving
chemotherapy or pelvic radiotherapy [43]. Follicular viability
after cryopreservation and thawing has been demonstrated in
several studies [44-48].
The risks of ovarian tissue cryopreservation include
reimplantation of the primary tumor, malignant transformation,
and risks related to the invasiveness of the procedure.
Limiting factors with this method are that it remains in
experimental status, the availability of the procedure in only a
few selected centers, and the limited life of the ovarian grafts.
Questions in the field of ovarian tissue cryopreservation that
are still unanswered include the optimal site for retransplan-
tation, the size of the ovarian grafts, and the effect of
gonadotropin stimulation [39].
In vitro fertilization after breast cancer
An increase in estradiol during controlled ovarian hyper-
stimulation may not be safe in women diagnosed with
estrogen-sensitive breast cancer who are seeking fertility
preservation. It has been clearly shown that estrogen stimu-
lates breast cancer cell growth, even at low concentrations
[49,50].
The embryo yield with natural-cycle IVF (without hormone
stimulation), however, is very low [51]. In such cases,
alternative stimulation regimens can be used – for example,
tamoxifen [52] or aromatase inhibitors [53] – although these
regimens are less effective without added gonadotropins.
Although these medications should not be used during
pregnancy, studies with tamoxifen and letrozole have
demonstrated that their short-term use for ovulation induction
does not adversely affect oocyte and embryo development.
Moreover, no detrimental effects on fetal development have
been demonstrated. In any case, clomiphene, a compound
related to tamoxifen, has been safely used for ovulation
induction for almost four decades [54].
In a study by Oktay and colleagues, tamoxifen 40–60 mg was
started on day 2 or day 3 of the cycle and was administered
daily for 5–12 weeks. The control group consisted of patients
with an unstimulated IVF cycle. The tamoxifen group had a
significantly higher number of mature oocytes, higher peak
Available online http://breast-cancer-research.com/content/10/2/206
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embryos versus 0.6 embryos) than the natural-cycle group [52].
Third-generation aromatase inhibitors (letrozole, anastrozole,
and exemestane) entered clinical practice initially as first-line
and second-line agents for the treatment of breast cancer
[55,56]. The use of aromatase inhibitors for ovulation induc-
tion was first reported in 2001; letrozole was reported to
provide superior results to clomiphene and was associated
with 50% lower estradiol levels [57]. Many groups are
currently testing the feasibility of ovarian stimulation with
aromatase inhibitors in patients with breast cancer and in
patients with endometrial cancer. The patient is stimulated
with gonadotropins, and an aromatase inhibitor is simul-
taneously introduced to reduce serum estradiol levels.
Oocyte development is unaffected. A luteinizing hormone-
releasing hormone antagonist is also used to prevent a
premature luteinizing hormone surge [58].
Oktay and colleagues compared the combination of
tamoxifen or letrozole with FSH for stimulation in women with
breast cancer, with very promising results [51]. Letrozole–
FSH and tamoxifen-alone stimulation were associated with
significantly lower peak estradiol levels than tamoxifen–FSH
stimulation. The combined letrozole–FSH protocol resulted in
peak estradiol levels close to those seen in unstimulated
cycles, and breast cancer recurrence rates were not
increased compared with controls [59]. The same group also
reported the first pregnancy from cryopreserved embryos
generated after tamoxifen stimulation [51], and reported that
breast cancer patients who underwent ovarian stimulation
with anastrozole had a significantly higher exposure to
estradiol than those who were stimulated with letrozole [60].
Nevertheless, Partridge and Winer have listed a series of
questions that remain unanswered [61]. How does even brief
exposure to high estrogen levels through tamoxifen or
FSH–letrozole stimulation affect the risk of breast cancer
recurrence? Does brief exposure to tamoxifen or letrozole
before treatment compromise the effect of chemotherapy?
Finally, do these substances have any influence on the quality
of the oocytes harvested?
Pregnancy after breast cancer
Pregnancy after breast cancer is another area of investigation
(Table 3) [62-72]. The incidence of live births after breast
cancer is very small. Among women <45 years of age at
diagnosis, only 3% have full-term pregnancy [70]; and among
women <35 years at diagnosis, 8% give birth to a liveborn
infant [71]. There has been concern that continued menstrual
cycling or pregnancy after breast cancer may worsen the
prognosis, since breast cancer is often hormone sensitive.
In a Finnish study among 2,548 women <40 years old
diagnosed with carcinoma of the breast during 1967 to
1989, there were 91 eligible patients with subsequent
deliveries (≥10 months after the diagnosis) – for whom 471
control individuals were matched for stage, age, and year of
breast cancer diagnosis. The controls had a 4.8-fold (95%
CI, 2.2 to 10.3) risk of death in comparison with those who
were delivered after the diagnosis of breast cancer. This
result was interpreted as a healthy mother effect (that is, only
women who feel healthy give birth and those who are
affected by the disease do not). Nevertheless, six of eight
deaths among the 91 patients who did give birth were related
to breast cancer [64].
A very interesting study investigated the prognostic influence
of pregnancies 5 years before (n = 173) and 5 years after
(n = 50) breast cancer diagnosis in 2,119 women younger
than 50 years of age with a primary operable breast cancer
[65].  Women who had undergone a pregnancy before
diagnosis had slightly larger tumors than the control group. The
women did not differ, however, with respect to nodal status or
estrogen receptor status. There was no evidence that women
who had undergone a pregnancy during the 5-year period
preceding the diagnosis of breast cancer had a poorer
prognosis in comparison with women who had not been
pregnant in the same period. Similarly, there was no evidence
that women who became pregnant after the diagnosis of
breast cancer had a poorer prognosis. In fact, the relative
hazard for women who became pregnant after a diagnosis of
breast cancer in comparison with women without a
subsequent pregnancy was 0.48 (P = 0.14), suggesting a
possibly reduced risk of distant dissemination [65].
Müller and colleagues retrospectively compared 438 patients
who became pregnant after a diagnosis of breast cancer, on
the one hand, with 2,775 control patients without preg-
nancies, on the other. They found that women who had births
at least 10 months after the cancer diagnosis had a signifi-
cantly lower mortality risk [70].
A Danish study examined 173 women, from a total population
of 5,725 women with primary breast cancer, who became
pregnant after treatment. Women who had a full-term preg-
nancy after breast cancer treatment had a nonsignificantly
reduced risk of death (relative risk 0.55; 95% CI, 0.28 to
1.06) in comparison with women who did not have a full-term
pregnancy. Neither miscarriages nor induced abortions after
breast cancer treatment influenced the prognosis [67].
Partridge and Ruddy postulate that there might even be a
beneficial biological effect of the high hormonal levels of preg-
nancy, since high-dose estrogen and progestins have been con-
ventionally used as a treatment modality for breast cancer [73].
A Japanese research group demonstrated an antitumor effect
in an animal model, possibly due to signaling via the insulin
growth factor pathway [74]. In the same animal model, it was
found that early age at full-term pregnancy or short-term
hormone treatment mimicking pregnancy may suppress the
Breast Cancer Research    Vol 10 No 2 Maltaris et al.
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crucial factor, however, because hormone exposure mimick-
ing pregnancy in aged individuals may exert effects that are
the opposite of those exerted in younger individuals [75].
The optimal timing of a subsequent pregnancy after breast
cancer is unclear and depends on the patient’s prognosis,
age, and personal situation. Meirow and Schiff postulated
that patients who recover from ovarian failure after high-dose
chemotherapy or radiotherapy treatments should not delay
childbearing for too many years. These patients should try to
conceive after a disease-free interval of a few years, but not
<6 to 12 months after the treatment, due to the possible toxic
effects of the therapy on growing oocytes [76]. A delay of 2
to 3 years after the cancer treatment is conventionally recom-
mended, so that the period associated with the greatest risk
of recurrence has passed before a pregnancy. In patients
with hormone-positive cancers, tamoxifen and GnRH
analogues do not cause permanent amenorrhea, but this
treatment can last up to 5 years, during which a pregnancy is
contraindicated [7].
In summary, an analysis of a number of studies in a population
of over 15,000 women, including more than 1,100 breast
cancer patients, demonstrates that there are at present no
conclusive data to suggest any deleterious effects, such as
an increased risk for relapse, due to subsequent pregnancy in
women with a history of breast cancer. A limiting factor in this
analysis is that none of the studies concerned was
randomized and controlled. Performing a randomized trial on
this specific issue is not possible, however, since no woman
can be denied the right to become pregnant. Notwithstanding
all the above, two studies published in the New England
Journal of Medicine [77,78] have reported that good
observational studies can give results similar to those of
randomized controlled trials [31].
It is therefore our firm belief that fertility preservation options
should be discussed with these patients.
Prognostic factor of amenorrhea
Chemotherapy-induced amenorrhea may be reversible;
however, the vast majority of women who remain amenorrheic
1 year after treatment do not regain ovarian function. Less
than 11% of women over 40 years old and only 12% to 15%
of younger women experience a return of menses after 1 year
of amenorrhea [7].
Ovarian estrogens play an important role in the oncogenesis
and development of breast cancer. The positive effect of
ovarian hormone suppression in the preventive situation, the
adjuvant situation, and also the palliative situation has been
adequately proven. There is no doubt that, particularly in very
young patients, chemotherapy acts at least partially via
chemotherapy-induced amenorrhea [79-82].
The fact that both ovarian suppression and chemotherapy
produce an improvement in the disease-free survival for
premenopausal women poses the question of whether this
effect is mediated at least partly by the same biochemical
pathways – a hypothesis that may be supported by the
following four points [83].
Available online http://breast-cancer-research.com/content/10/2/206
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Table 3
Effect of a subsequent pregnancy on outcome in breast cancer survivors
Relative risk 
(95% confidence interval) 
Patients  Controls  of recurrence or death/
Reference Year (n)( n) % recurrence Outcome
Ariel and Kempner [62] 1989 47 30% recurrence No adverse effect on survival
Sutton and colleagues [63] 1990 23 204 28% recurrence, 3 deaths No adverse effect on survival
Sankila and colleagues [64] 1994 91 471 0.20 (0.10 to 0.50) No adverse effect on survival
von Schoultz and colleagues [65] 1995 50 2,119 0.48 (0.18 to 1.29) No adverse effect on survival
Malamos and colleagues [66] 1996 21 222 14.3% recurrence No adverse effect on survival
Kroman and colleagues [67] 1997 173 5,514 0.55 (0.28 to 1.06) Decreased risk in pregnant women
Velentgas and colleagues [68] 1999 3 265 0.80 (0.30 to 2.30) No adverse effect on survival
Gelber and colleagues [69] 2001 94 94 0.44 (0.21 to 0.46) Decreased risk in pregnant women
Müller and colleagues [70] 2003 438 2,775 0.54 (0.41 to 0.71) Decreased risk in pregnant women
Blakely and colleagues [71] 2004 47 323 0.70 (0.25 to 1.95) No adverse effect on survival
Ives and colleagues [72] 2007 123 2,416 0.59 (0.37 to 0.95) Decreased risk in pregnant women
Total 1,110 14,164First, cytotoxic chemotherapy will induce amenorrhea in a
proportion of premenopausal women, ranging from about
15% to close on 100%, depending on age. The younger the
woman, the greater the resistance to the castrating effect of
cytotoxic drugs [5].
Second, the endocrinological profile of a woman exposed to
cytotoxic chemotherapy is similar to that of a castrate woman.
In other words, estradiol levels fall and gonadotropin levels
rise [84,85].
Third, there is now extensive literature illustrating the fact that
the induction of amenorrhea by adjuvant cytotoxic chemo-
therapy or endocrine therapy is in itself a prognostic factor.
Those women who develop permanent amenorrhea fare
better than those whose menstrual periods return during or
after the completion of the course of treatment. This
association is seen most clearly amongst women whose
tumors express the estrogen/progesterone receptors [86-
88]. A meta-analysis on the influence of chemotherapy-
induced amenorrhea on the prognosis has demonstrated a
significant advantage of survival for amenorrheic patients in
15 of 23 studies included [89]. Similarly, a meta-analysis of
randomized studies including 3,307 patients confirmed a
significant difference in the overall survival (15% reduction,
P = 0.04) with GnRH therapy after chemotherapy [90].
Altogether, the available data allow the conclusion that
chemotherapy-induced amenorrhea or amenorrhea after
GnRH therapy following chemotherapy improves the prognosis.
Finally, there have been trials that have attempted to carry out
a direct comparison of endocrine therapy and chemotherapy
in premenopausal women. In a recent meta-analysis, data
from 11,906 premenopausal women with early breast cancer
who were randomly assigned to treatments in 16 trials were
examined. When used as the only systemic adjuvant
treatment, luteinizing hormone-releasing hormone agonists
did not significantly reduce the recurrence rate (28.4%
relative reduction; 95% CI consistent with a 50.5% reduction
to a 3.5% increase; P = 0.08) or the rate of death after
recurrence (17.8%; 95% CI consistent with a 52.8% reduc-
tion to a 42.9% increase; P = 0.49) with hormone-receptor-
positive cancers. The addition of luteinizing hormone-
releasing hormone agonists to tamoxifen or chemotherapy, or
to both, reduced the recurrence rate by 12.7% (95% CI, 2.4
to 21.9; P = 0.02) and reduced the rate of death after
recurrence by 15.1% (95% CI, 1.8 to 26.7; P = 0.03).
Luteinizing hormone-releasing hormone agonists showed
similar efficacy to chemotherapy (recurrence, 3.9% increase;
95% CI consistent with a 7.7% reduction to 17.0% increase;
and death after recurrence, 6.7%; 95% CI consistent with a
reduction, 20.7% reduction to 9.6% increase; neither signifi-
cant). No trials have assessed a luteinizing hormone-releasing
hormone agonist versus chemotherapy with tamoxifen in both
arms. Luteinizing hormone-releasing hormone agonists were
ineffective in hormone receptor-negative tumors [34].
Conclusion
Young female breast cancer patients are still being poorly
counseled with regard to the negative impact of the treatment
on their fertility and on their options for fertility preservation.
Although there have been a few studies that show a positive
effect of GnRH analogues on fertility preservation, there is
insufficient evidence to establish the use of GnRH analogues
as a first-line therapy. There are currently a few ongoing
prospective randomized studies on the topic, but their long-
awaited results will probably not yet be published for several
years. In the meantime, the use of GnRH analogues in breast
cancer patients should be offered in the context of clinical
trials after adequate counseling of the patients with regard to
the possible influence of this treatment on the effectiveness
of chemotherapy. Other methods of preserving fertility, such
as ovarian tissue cryopreservation, in vitro maturation, and
IVF after ovulation induction with aromatase inhibitors, should
also be discussed with the patient. Pregnancy after breast
cancer treatment does not appear to limit the prognosis.
The present review has focused both on the effects of cancer
treatments on fertility and on the various assisted-repro-
duction innovations that are available to provide the breast
cancer patient with the option of future pregnancies. We are
currently passing through a period of uncertainty and change
with regard to the role of ovarian suppression and other
fertility preservation measures in the management of early
breast cancer, but developments in the near future promise to
be very exciting.
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